About this episode

This episode discusses recent advancements in diabetes treatment, including the introduction of retatrutide and comparisons with other medications.

This week on Hormone Insight: the fallout from the ADA 2026 Scientific Sessions, where retatrutide — a triple GIP/GLP-1/glucagon agonist — delivered nearly 2 points of A1C and about 15% weight loss in type 2 diabetes (TRANSCEND-T2D-1). Plus CagriSema vs semaglutide head-to-head, finerenone in chronic kidney disease without diabetes, the new ADA/EASD type 1 diabetes consensus, and a Hormone Classic revisit of SUSTAIN-6 — the outcome bar every new drug still has to clear. Segments: • Trial of the Week — Retatrutide in type 2 diabetes (TRANSCEND-T2D-1, The Lancet) • Quick Hit 1 — CagriSema vs semaglutide (REIMAGINE 2, Lancet Diabetes & Endocrinology) • Quick Hit 2 — Finerenone in CKD without diabetes (FIND-CKD, NEJM) • Guideline & FDA Watch — ADA/EASD type 1 diabetes in adults: 2026 consensus update • Hormone Classic — SUSTAIN-6 (semaglutide cardiovascular outcomes, 2016) ⏱ Chapters 00:00 Cold open 00:38 Welcome & disclaimer 01:02 This week 01:47 Trial of the Week — Retatrutide (TRANSCEND-T2D-1) 03:51 The Appraisal 04:59 Bottom line — retatrutide 05:29 Quick Hit 1 — CagriSema vs semaglutide 06:54 Quick Hit 2 — Finerenone in CKD without diabetes 08:04 Guideline & FDA Watch — ADA/EASD…

More episodes of Hormone Insight

• STEP 1 Trial Explained: Semaglutide 2.4 mg for Obesity in 2 Minutes · June 28, 2026 · 2 min
• An Oral GLP-1 That Works: ATTAIN-2 and the 2026 ADA Standards | This Week in Diabetes & Endocrinology · June 20, 2026 · 10 min

Explore listener stats, chart rankings, contacts and more on the Hormone Insight podcast page.